Deal Watch: Endo Hopes To Boost Generics Unit With Buy-Out Of Par
J&J is teaming with Achillion to produce a combo regimen for hepatitis C that might compete with offerings from Gilead, AbbVie and Merck. Amgen is dropping out of its collaboration on brodalumab with AstraZeneca due to concerns about suicidality in clinical trials.
You may also be interested in...
Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal
Deal activity over the past week saw AstraZeneca stealthily increase its commitment to mRNA player Moderna, Gilead seek innovation in HIV through an alliance with Genmab for its bispecific antibody technology, and Hospira back out of a licensing deal for Pfenex's Lucentis biosimilar, and more.
Danish insulin maker’s decision triggered by failure of its most advanced compound, anti-IL-20, for the treatment of rheumatoid arthritis.
French biotech Innate Pharma is set to take the anti-NKG2A antibody IPH2201 into Phase II after buying out rights from Novo Nordisk for €2 million up front.